TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20139566
Drug: Self‐etch 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐etch 1 step (Adper Prompt L‐Pop, 3M ESPE‐LP)
Study: 16912024
Drug: delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delapril 30 mg twice daily
Study: 16912024
Drug: delapril 15
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delapril 15 mg twice daily
Study: 16912024
Drug: delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delapril 30 mg once daily
Study: 16912024
Drug: delapril 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: delapril 7.5 mg twice daily
Study: 7993326
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 5, 10, and 20% carbon dioxide (CO2)
Study: 7993326
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of room air
Study: 2701745
Drug: Buspirone (BUS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (BUS, 10 mg)
Study: 2701745
Drug: Diazepam (DZP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (DZP, 10 mg)
Study: 28847326
Drug: Scrub 1
Normalized name: E-Z Scrub 107 4 % Medicated Liquid Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrub 1 (scrubs with a complex element compound with a silver-alloy embedded in its fibers)
Study: 23500091
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg IM every 4 weeks
Study: 11550733
Drug: Hypnotic-relaxation training
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic-relaxation training
Study: 11550733
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hypnotic-relaxation training)
Study: 9593133
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of sulbactam with 2,000 mg of ampicillin by intravenous bolus injection (3 min), repeated after 2 hours.
Study: 9593133
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of sulbactam with 2,000 mg of ampicillin by bolus injection (3 min) followed by a continuous infusion of the same dose over 4 hours.
Study: 8112244
Drug: Carbamazepine-CR (CBZ-CR)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine-CR (CBZ-CR) 20 mg/kg as a single loading dose
Study: 8112244
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) 20 mg/kg (two-thirds at 0 h and one-third at 2 h)
Study: 27718000
Drug: bosutinib with
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bosutinib with aprepitant (125 mg × 1)
Study: 27718000
Drug: bosutinib alone
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bosutinib alone (100 mg × 5)
Study: 25380241
Drug: BV 1
Normalized name: Epivir HBV 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV 1 treatment (1:10,000 concentration BVA plus physiotherapy)
Study: 25380241
Drug: BV 2
Normalized name: Epivir HBV 25 MG in 5 mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV 2 treatment (1:30,000 concentration BVA plus physiotherapy)
Study: 25380241
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (normal saline injection plus physiotherapy)
Study: 22466026
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group (20 minutes of daily postural and movement activities for 4 weeks)
Study: 15353542
Drug: Intensive postremission
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive postremission chemotherapy
Study: 15353542
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive postremission chemotherapy
Study: 15353542
Drug: Standard four-drug/4-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard four-drug/4-week induction course
Study: 11594640
Drug: Increased intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased intensity of rehabilitation therapy input without change in content
Study: 2144208
Drug: Zoladex 3.6
Normalized name: Zoladex 3.6mg Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex 3.6 mg as a depot preparation combined with flutamide 250 mg tid
Study: 30536932
Drug: Nurse-led sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led sleep programme (4 weekly 1-hr sessions)
Study: 23601796
Drug: Isotonic balanced
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic balanced solutions (crystalloid and hydroxyethyl starch; balanced group)
Study: 23601796
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solutions (crystalloid and hydroxyethyl starch; saline group)
Study: 18236999
Drug: Montelukast (oral)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (oral)
Study: 11375295
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus low doses of conjugated equine estrogen
Study: 11375295
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus conventional doses of conjugated equine estrogen
Study: 11375295
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus low doses of calcitriol
Study: 11375295
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus conventional doses of calcitriol
Study: 9366972
Drug: Peptide T
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide T high dose (15 mg daily for four weeks)
Study: 9366972
Drug: Peptide T
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide T low dose (1.5 mg daily for four weeks)
Study: 9366972
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of high dose versus low dose Peptide T
Study: 1760535
Drug: Felodipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 1.25 mg
Study: 20615108
Drug: SMS-based insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SMS-based insulin dose titration system
Study: 20615108
Drug: Conventional titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional titration scheme
Study: 10573242
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with salmeterol (50 microg b.i.d.) and beclomethasone (400 microg b.i.d.)
Study: 10573242
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with beclomethasone (400 microg b.i.d.)
Study: 10573242
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with salmeterol (50 microg b.i.d.)
Study: 27050252
Drug: Vitamin D-K-Calcium
Normalized name: calcium carbonate / cholecalciferol / vitamin K Chewable Tablet [Viactiv Calcium Plus D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-K-Calcium co-supplementation (200 IU vitamin D, 90 μg vitamin K, 500 mg calcium)
Study: 17877601
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (Group C)
Study: 15085026
Drug: Nizatidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (2 or 4 mg/kg i.v. for infants; 2.5 or 5 mg/kg oral for children; 150 mg capsule for adolescents and adults)
Study: 15085026
Drug: Nizatidine administration
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine administration
Study: 10374157
Drug: Heparin-surface-modified (HSM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified (HSM) intraocular lenses (IOLs)
Study: 3329126
Drug: Sucrose-enriched diet
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose-enriched diet (about 20 g sucrose per day)
Study: 31912903
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene regimen (OHR) for 2 weeks
Study: 28787506
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg, 3 times a week for 2 years)
Study: 26245599
Drug: Multiforce® (MF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiforce® (MF) Alkaline Powder, 7.5 g twice daily
Study: 23117443
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (telephone monitoring and treatment as usual)
Study: 18428211
Drug: Lamotrigine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (target dose of 300 mg/day)
Study: 8247917
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with DTZ SR-HCTZ 120 mg-12.5 mg
Study: 8247917
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with DTZ SR 120 mg
Study: 8247917
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with HCTZ 12.5 mg
Study: 31299247
Drug: Oropharyngeal spray
Normalized name: MENTHOL 1.8 mg in 10 mL OROPHARYNGEAL SPRAY [Heshoutang PuraFlex OmniRelief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal spray (10 actuations of 10% lignocaine, group B)
Study: 17468862
Drug: Curcumin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (300 mg day(-1) for 6 days)
Study: 17468862
Drug: Talinolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol (50 mg single oral dose)
Study: 8489440
Drug: Prophylactic surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic surfactant therapy
Study: 3829723
Drug: Aqueous anthralin
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous anthralin cream (Drithocreme) applied overnight
Study: 3829723
Drug: Aqueous anthralin
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous anthralin cream (Drithocreme) applied for thirty minutes
Study: 23526939
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed eGFR formulas (eGFR7 and eGFR8) using serum CysC detection alone or in combination with serum Cr detection
Study: 10549683
Drug: Zolpidem, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem, 10 mg nightly for 4 weeks
Study: 2050833
Drug: Moclobemide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (100 mg TID)
Study: 2050833
Drug: Phenelzine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (15 mg TID)
Study: 6219902
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate tablets (500 mg twice a day for 2 weeks)
Study: 6219902
Drug: Erythromycin enteric-coated
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin enteric-coated base capsules (500 mg twice a day for 2 weeks)
Study: 24578164
Drug: Resynchronization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resynchronization therapy (CRT-D)
Study: 19053987
Drug: pantoprazole 80
Normalized name: pantoprazole 80 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 80 mg + 8 mg/h for 72 h
Study: 19053987
Drug: ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 50 mg + 13 mg/h for 72 h
Study: 16891136
Drug: levalbuterol 0.31
Normalized name: levalbuterol 0.31 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: levalbuterol 0.31 mg via nebulizer
Study: 16891136
Drug: levalbuterol 0.63
Normalized name: levalbuterol 0.63 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: levalbuterol 0.63 mg via nebulizer
Study: 16891136
Drug: racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: racemic albuterol 1.25 mg via nebulizer
Study: 16891136
Drug: racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: racemic albuterol 2.5 mg via nebulizer
Study: 16891136
Drug: (S)-albuterol presence
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-albuterol presence
Study: 15088306
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg (2.5 ml) hyaluronan (HA) in a phosphate buffered solution
Study: 15088306
Drug: Saline vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline vehicle (2.5 ml vehicle containing only the buffer)
Study: 15088306
Drug: Intraarticular HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular HA treatment
Study: 9635603
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (50 mg three times a day)
Study: 3042126
Drug: Flunarizine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (15 mg/day)
Study: 30744880
Drug: Omega-3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 LCPUFA (722 mg/day DHA)
Study: 30744880
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2000 IU/day) + Omega-3 LCPUFA (722 mg/day DHA)
Study: 28097633
Drug: Individualized meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized meropenem therapy based on a population PK/PD model
Study: 15175633
Drug: Sour milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sour milk fermented with Lactobacillus helveticus containing 2.4-2.7 mg of Ile-Pro-Pro and 2.4-2.7 mg of Val-Pro-Pro per 1.5 dl, taken daily.
Study: 15175633
Drug: Placebo (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (regular sour milk), taken daily.
Study: 9719049
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (0.3 U/kg body wt per day)
Study: 7654109
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (combined response rate)
Study: 2655256
Drug: Metimazole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metimazole (2.5 g)
Study: 334611
Drug: Butacote (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butacote (300 mg daily)
Study: 334611
Drug: fenclofenac (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenclofenac (1200 mg daily)
Study: 25916220
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 μg twice daily for 12 weeks
Study: 21192244
Drug: Artesunate-Amodiaquine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-Amodiaquine (both formulations)
Study: 21609157
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT)‐based brief intervention and education program
Study: 11726841
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection therapy (epinephrine and polidocanol)
Study: 11726841
Drug: No endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endoscopic therapy (control group)
Study: 3309199
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate (MTX) 15 mg
Study: 3309199
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate (MTX) 15 mg plus cytosine arabinoside (Ara-C) 50 mg/m2
Study: 3309199
Drug: Drugs administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs administered via Ommaya reservoir
Study: 3309199
Drug: Drugs administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs administered via lumbar puncture
Study: 3309199
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy to the CNS
Study: 3309199
Drug: No concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concurrent radiotherapy to the CNS
Study: 31545914
Drug: 1,25(OH)2D3 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 (100 nmol/L, 12 h)
Study: 29345161
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg/kg body weight, 60 min pretrial)
Study: 18490931
Drug: Cod diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod diet (3 x 150 g week(‐1))
Study: 18490931
Drug: Salmon diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon diet (3 x 150 g week(‐1))
Study: 17502874
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (DHA/EPA capsules, no seafood)
Study: 15986036
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) with continuous infusion 5-FU (CI 5-FU)
Study: 12185157
Drug: Off condition
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off condition (no treatment)
Study: 12185157
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Deep brain stimulation, Levodopa, both)
Study: 359110
Drug: Meperidine 75
Normalized name: MEPERIDINE 75MG/ML INJ CARPUJECT LL 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 75 to 150 mg
Study: 30907180
Drug: Nutritional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional treatment (Control Group)
Study: 31161927
Drug: Shilajit supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shilajit supplementation (125 or 250 mg bid)
Study: 31161927
Drug: Shilajit supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shilajit supplementation (250 mg bid)
Study: 26081815
Drug: Cediranib (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (an inhibitor of vascular endothelial growth factor receptors) combined with carboplatin-paclitaxel
Study: 16132055
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g per day of water-soluble fiber from oat bran
Study: 11762655
Drug: Anticonvulsant medication
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant medication
Study: 10960380
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 1.5% (60‐mg dose) plain mepivacaine (Group 1)
Study: 10960380
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 2% (80‐mg dose) plain mepivacaine (Group 2)
Study: 10960380
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of plain mepivacaine
Study: 17434095
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH), nadroparin calcium 3800 anti-factor Xa IU/0.4 mL twice daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Study: 17434095
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Study: 15685040
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with DDP (80 mg/m2 intravenously day 1 only) and VP-16 (80 mg/m2 intravenously days 1-3) every 3 weeks for 5 cycles without tamoxifen.
Study: 15685040
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with DDP and VP-16 plus high-dose tamoxifen (80 mg orally twice per day for 5 days each cycle starting 1 day before DDP).
Study: 11854640
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (200 microg initially, increased to 300 microg)
Study: 7541064
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and didanosine combination therapy for 2 years
Study: 2355814
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) 500 mg
Study: 30590606
Drug: Post-operative therapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative therapy with capecitabine and oxaliplatin
Study: 20500533
Drug: High adherence
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High adherence to drug (> 80% of days covered)
Study: 20500533
Drug: Low adherence
Normalized name: dressing,low adherence and wound contact materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low adherence to drug (< 50% of days covered)
Study: 12365468
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of metformin
Study: 10585981
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of Adderall received in the morning only